Kamada
$ 9.31
1.20%
25 Feb - close price
- Market Cap 537,014,000 USD
- Current Price $ 9.31
- High / Low $ 9.35 / 9.19
- Stock P/E 26.60
- Book Value 4.51
- EPS 0.35
- Next Earning Report 2026-03-04
- Dividend Per Share N/A
- Dividend Yield 3 %
- Next Dividend Date -
- ROA 0.05 %
- ROE 0.08 %
- 52 Week High 9.35
- 52 Week Low 5.54
About
Kamada Ltd. develops, produces and markets plasma-derived protein therapies for orphan indications. The company is headquartered in Rehovot, Israel.
Analyst Target Price
$13.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-10 | 2025-08-13 | 2025-05-06 | 2025-03-04 | 2024-11-11 | 2024-08-14 | 2024-05-08 | 2024-03-06 | 2023-11-13 | 2023-08-16 | 2023-05-24 | 2023-03-15 |
| Reported EPS | 0.29 | 0.19 | 0.07 | 0.07 | 0.07 | 0.08 | 0.04 | 0.09 | 0.06 | 0.04 | -0.04 | 0.07 |
| Estimated EPS | 0.09 | 0.08 | 0.0675 | 0.0533 | 0.07 | 0.06 | 0.06 | 0.05 | 0.03 | 0.02 | 0.03 | 0.07 |
| Surprise | 0.2 | 0.11 | 0.0025 | 0.0167 | 0 | 0.02 | -0.02 | 0.04 | 0.03 | 0.02 | -0.07 | 0 |
| Surprise Percentage | 222.2222% | 137.5% | 3.7037% | 31.3321% | 0% | 33.3333% | -33.3333% | 80% | 100% | 100% | -233.3333% | 0% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-04 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.09 |
| Currency | USD |
Previous Dividend Records
| Apr 2025 | |
|---|---|
| Payment Date | 2025-04-07 |
| Amount | $0.2 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: KMDA
2026-02-25 21:52:48
Kamada (NASDAQ:KMDA) is projected to release its Q4 2025 earnings before market open on Wednesday, March 4, 2026, with analysts expecting $0.09 EPS and $145.067 million in revenue. The biopharmaceutical company currently has an average "Moderate Buy" rating from Wall Street analysts and an average price target of $14.00, while institutional ownership stands at around 20.4%. Its stock performance shows a 1-year range of $5.54–$9.27, with a current market cap of $529.09 million.
2026-01-29 06:59:54
Kamada (TLV:KMDA) has provided favorable returns to its shareholders, with a 74% Total Shareholder Return (TSR) over the last three years, which surpasses its 69% share price growth. The company has also transitioned from a loss to profitability during this period, contributing to the positive sentiment. While its annual return of 13% lagged the broader market in the last year, it exceeded the average 3% over five years, suggesting growing investor interest.
2026-01-29 04:57:27
Kamada Ltd. (TLV:KMDA) has provided favorable returns to its shareholders, with a total shareholder return (TSR) of 74% over the last three years, outperforming its share price gain of 69% in the same period, primarily due to dividends. The company also turned profitable during this time, contributing positively to investor sentiment. In the last year, shareholders saw a 13% gain, though this was below the broader market return.
2026-01-23 12:28:19
Kamada Ltd. (KMDA), an Israeli biopharmaceutical company, is drawing attention with a 62.91% potential upside in the healthcare sector. The company, which specializes in plasma-derived protein therapeutics, has a market capitalization of $460.3 million and innovative products addressing critical healthcare needs. With strong analyst buy ratings, a bullish technical outlook, and efficient financial management, Kamada is positioned for continued growth and presents a compelling opportunity for investors.
2026-01-22 09:57:34
Kamada Ltd's stock (KMDA) has been underperforming, with shares trending downwards and testing investor patience. The biopharma company, specializing in niche plasma and respiratory therapies, lacks recent catalysts, leading to a cautious stance from Wall Street and a "Hold" consensus from analysts. Kamada's future depends on consistent revenue growth, pipeline advancements, and navigating macro-economic risks, appealing mainly to long-term, risk-tolerant investors.
2026-01-17 05:58:34
Kamada Ltd. (NASDAQ: KMDA) anticipates significant growth in 2026, targeting a 13% increase in revenue to $200-$205 million and a 23% rise in adjusted EBITDA to $50-$53 million. This organic growth is expected to be fueled by its specialty plasma therapies, distribution segment, and increased plasma collection capabilities. The company also plans to pursue new business development deals and acquisitions to further enrich its product portfolio and generate synergies.
